CD274 and neoplasm: Tumor-activated “prodrug” antibodies, such as the protease-activated anti-PD-L1 Probody pacmilimab (CX-072), further exemplify conjugate or masked designs that aim to retain systemic exposure while reducing off-tumor toxicity by unmasking the antigen-binding site preferentially within the tumor microenvironment (146).